Adoptive transfer of tumor-reactive CD8+ T lymphocytes is one of the most effective immunotherapy approaches for the treatment of solid tumors.1 Muranski and colleagues show that a recently identified population of CD4+ T lymphocytes called Th17 cells possesses unexpected antimyeloma therapeutic properties.
Th17 and cancer: friends or foes?
Bronte, Vincenzo
2008-01-01
Abstract
Adoptive transfer of tumor-reactive CD8+ T lymphocytes is one of the most effective immunotherapy approaches for the treatment of solid tumors.1 Muranski and colleagues show that a recently identified population of CD4+ T lymphocytes called Th17 cells possesses unexpected antimyeloma therapeutic properties.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
